Pliant Therapeutics, Inc.
Extract: Bylaws Amended/Restated (Plain English Desc) from a 8-K on 09/27/2024
SEC Document
SEC Filing

On September 24, 2024, the Board of Directors of Pliant Therapeutics, Inc. (the “Company”) approved the amendment and restatement of the Bylaws of the Company (as so amended and restated, the “Third Amended and Restated Bylaws”). The Third Amended and Restated Bylaws are effective as of September 24, 2024.

The amendments effected by the Third Amended and Restated Bylaws, among other things: (i) align the Company’s bylaws with developments in Delaware law and jurisprudence; (ii) revise the procedural and disclosure requirements applicable to stockholders’ director nominations and proposals for other business; and (iii) include a provision regarding severability. The Third Amended and Restated Bylaws also implement certain other ministerial and conforming changes.